Argenx
ARGX
#422
Rank
NZ$96.46 B
Marketcap
NZ$1,549
Share price
-0.55%
Change (1 day)
48.02%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): NZ$1.64 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$3.60 Billion. In 2024 the company made an earning of NZ$0.14 Billion, an increase over its 2023 earnings that were of -NZ$0.53 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.64 B1018.34%
2024 NZ$0.14 B-127.97%
2023 -NZ$0.53 Billion-58.25%
2022 -NZ$1.27 Billion
2019 -NZ$0.35 Billion124.86%
2018 -NZ$0.16 Billion131.81%
2017 -NZ$65.97 Million54.9%
2016 -NZ$42.59 Million33.71%
2015 -NZ$31.85 Million12.93%
2014 -NZ$28.21 Million46.39%
2013 -NZ$19.27 Million